Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

LGD-4033 well tolerated in healthy volunteers at multiple doses

June 9, 2011

Merck & Co. synthesizes novel histamine H3 receptor antagonists

June 9, 2011

SPX-106 with D-tagatose significantly reduces cholesterol and triglycerides in mice

June 7, 2011

Mellitech researchers disclose new insulin secretagogues

June 7, 2011

Liraglutide added to insulin shows promise in treating type 1 diabetes

June 7, 2011

Vitae and Boehringer Ingelheim claim new 11-beta-HSD1 inhibitors

June 7, 2011

Orexigen Therapeutics to appeal FDA's decision regarding Contrave NDA

June 6, 2011

Phase III Get-Goal-L trial of lixisenatide in type 2 diabetes meets primary endpoint

June 6, 2011

New ghrelin receptor antagonists and/or inverse agonists synthesized

June 3, 2011

Diamyd Medical stops follow-up in European phase III study of Diamyd in diabetes

June 1, 2011

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 20, 2026.
ALN-5288 lowers tau levels in preclinical models
BioWorld Science
Pathological tau accumulation is a key driver of neurodegeneration in Alzheimer’s disease (AD) and other tauopathies such as progressive supranuclear palsy....
Capital remains selective in ‘barbell’ biotech market
BioWorld
Signs of recovery are emerging in the biotechnology investment sector, although investors across Asia say that capital is flowing selectively to companies that...
Dual FAAH/MAGL inhibition targets Alzheimer’s disease hyperexcitability
BioWorld Science
Reduced endocannabinoid signaling has been linked to neuronal hyperexcitability in Alzheimer’s disease (AD), suggesting that dual inhibition of fatty acid amide...
PSB-229 reduces plaque burden in Alzheimer’s models
BioWorld Science
Pyroglutamate-modified amyloid-β (pE3-Aβ) is a highly pathogenic Aβ species that accumulates within amyloid plaques and contributes to aggregation,...